Immunotherapy in the Initial Treatment of Newly Diagnosed Cancer Patients: Utilization Trend and Cost Projections for Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Metastatic Colorectal Cancer

Shih, Ya Chen Tina; Elting, Linda S.; Pavluck, Alexandre L.; Stewart, Andrew K.; Halpern, Michael T.

doi:10.3109/07357900902783187

Cited by 17 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the treatment of breast cancer, we included costs by treatment phase (initial, continuing, and terminal) and cancer stage (local, regional, and distant) ( Yabroff et al , 2008 ; Riley and Lubitz, 2010 ). In addition, we added costs associated with 5-year prescriptions of tamoxifen for women who are ER positive ( Allen, 2010 ) and trastuzumab costs for women who are HER2 positive ( Shih et al , 2010 ). Indirect costs from lost productivity for women who die prematurely from breast cancer (i.e., mortality costs resulting from lost wages) were estimated using age-specific wage rates for female workers in the labour market of the United States ( Day and Newburger, 2002 ).…”

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk

et al. 2014

View full text Add to dashboard Cite

Background:Magnetic resonance imaging (MRI) is recommended for women at high risk for breast cancer. We evaluated the cost-effectiveness of alternative screening strategies involving MRI.Methods:Using a microsimulation model, we generated life histories under different risk profiles, and assessed the impact of screening on quality-adjusted life-years, and lifetime costs, both discounted at 3%. We compared 12 screening strategies combining annual or biennial MRI with mammography and clinical breast examination (CBE) in intervals of 0.5, 1, or 2 years vs without, and reported incremental cost-effectiveness ratios (ICERs).Results:Based on an ICER threshold of $100 000/QALY, the most cost-effective strategy for women at 25% lifetime risk was to stagger MRI and mammography plus CBE every year from age 30 to 74, yielding ICER $58 400 (compared to biennial MRI alone). At 50% lifetime risk and with 70% reduction in MRI cost, the recommended strategy was to stagger MRI and mammography plus CBE every 6 months (ICER=$84 400). At 75% lifetime risk, the recommended strategy is biennial MRI combined with mammography plus CBE every 6 months (ICER=$62 800).Conclusions:The high costs of MRI and its lower specificity are limiting factors for annual screening schedule of MRI, except for women at sufficiently high risk.

show abstract

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk

et al. 2014

View full text Add to dashboard Cite

show abstract

“…For each patient, the estimated lifetime treatment cost ranges from $20,000-$100,000 9,10 . Although MBC accounts for a small proportion of all breast cancer cases, the economic burden of treating MBC is significant given the growing number of treatment options 11 . Additionally, since breast cancer is mostly prevalent in women of working age, indirect costs such as productivity loss should not be overlooked 8,9 .…”

Section: Introductionmentioning

confidence: 99%

Indirect costs associated with metastatic breast cancer

Yin

Gào

Mehta

et al. 2013

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

“…Drug cost alone for BEV-containing regimens is about twice as high as that for regimens without BEV among patients with metastatic colorectal cancer 8. Another study estimated that the initial treatment cost per person for BEV-containing regimens in metastatic colorectal cancer is around US$80,000 9. While the costs and cost-effectiveness of BEV in the treatment of metastatic colorectal cancer have been explored in numerous studies, less is known about the economics of BEV in NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)

Chien¹,

Shih²

2012

CEOR

View full text Add to dashboard Cite

BackgroundDelivering affordable cancer care is becoming increasingly important. Bevacizumab (BEV) is a costly molecular targeted agent effective for a variety of cancer including lung cancer. The objective of this review is to assess published economic evaluation of BEV in the treatment of non-small cell lung cancer (NSCLC).MethodsA literature search in PubMed, Cochrane, and the Health Technology Assessment reports for English-language publications before February 2012 was performed. Studies were independently screened by two reviewers, and eight publications were included in the review. The results of these eight articles were tabulated and all cost estimates were reported in 2011 US dollars.ResultsAmong the eight articles, three were cost studies and five were cost-effectiveness/utility analysis. For first-line treatment, BEV-containing regimen was reported to be the most costly regimen in one study but cost saving when compared with pemetrexed/cisplatin in another study. When compared with other regimens, BEV-containing regimen was reported to be cost effective in two cost-effectiveness studies (incremental cost-effectiveness ratio [ICER] in the range of US$30,318–US$54,317 per life year) but not cost effective in the other three studies (ICER over US$300,000 per life year).ConclusionIn this review of economic evaluation of BEV in the treatment of NSCLC, it was found that the literature was not conclusive on the economic benefit of BEV. The role of BEV in other treatment settings for NSCLC was unknown. Further studies, such as clinical trials with adequate power to compare the efficacy between low dose and high dose BEV, potential impact of predictive biomarkers for BEV, and comprehensive economic evaluation will strengthen the current state of knowledge on the economic value of BEV in NSCLC.

show abstract

Immunotherapy in the Initial Treatment of Newly Diagnosed Cancer Patients: Utilization Trend and Cost Projections for Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Metastatic Colorectal Cancer

Cited by 17 publications

References 28 publications

Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk

Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk

Indirect costs associated with metastatic breast cancer

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)

Contact Info

Product

Resources

About